Emergent BioSolutions EVP reports option grant, tax shares

Emergent BioSolutions EVP Coleen Glessner reported a stock option grant and a related tax-withholding share disposition.

Rhea-AI Filing Summary

Emergent BioSolutions EVP Coleen Glessner reported a stock option grant and a related tax-withholding share disposition. On March 3, she acquired 44,834 Employee Stock Options (right to buy common stock) as a grant with a stated price of $0.00 per option, which vest in three equal installments beginning on the day prior to each anniversary of the grant date.

On March 5, 8,199 shares of common stock were withheld and disposed of to cover taxes associated with the vesting and settlement of restricted stock units. After these transactions, she directly owned 104,108 shares of common stock and 294,447 stock options.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Glessner Coleen

Role EVP, Quality & Ethics, and CPL

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	8,199	$8.44	$69K
Grant/Award	Employee Stock Option (Right to buy)	44,834	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (Right to buy) — 294,447 contracts (Direct); Common Stock — 104,108 shares (Direct)

Footnotes (2)

1. F1. Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units
2. F2. Vests in three equal installments beginning on the day prior to the anniversary date of the grant.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Emergent BioSolutions (EBS) EVP Coleen Glessner report in this Form 4?

Coleen Glessner reported a stock option grant and a tax-related share disposition. She received 44,834 Employee Stock Options and had 8,199 common shares withheld to pay taxes tied to restricted stock unit vesting.

How many stock options did Coleen Glessner receive from Emergent BioSolutions (EBS)?

She received 44,834 Employee Stock Options, each representing a right to buy Emergent BioSolutions common stock. The grant price is listed as $0.00 per option, reflecting an award rather than a market purchase.

Why were 8,199 Emergent BioSolutions (EBS) shares disposed of in this filing?

The 8,199 common shares represent stock withheld to pay taxes from vesting and settlement of restricted stock units. This is a tax-withholding disposition, not an open-market sale, and is coded as a Form 4 "F" transaction.

How do the new stock options for Emergent BioSolutions (EBS) EVP vest over time?

The 44,834 Employee Stock Options vest in three equal installments. Vesting begins on the day prior to each anniversary of the grant date, spreading the award over three years according to the disclosed schedule.

What are Coleen Glessner’s Emergent BioSolutions (EBS) holdings after these transactions?

Following the reported transactions, she directly holds 104,108 shares of Emergent BioSolutions common stock. She also directly holds 294,447 Employee Stock Options, reflecting cumulative option awards after the latest grant.

Is the Emergent BioSolutions (EBS) insider transaction a buy or sell of shares?

The filing combines an option award and a tax-withholding share disposition. Glessner acquired 44,834 stock options as a grant and disposed of 8,199 common shares that were withheld solely to cover tax obligations on restricted stock unit vesting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/05/2026 - 09:06 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Glessner Coleen

(Last) (First) (Middle)

300 PROFESSIONAL DRIVE

(Street)

GAITHERSBURG MD 20879

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Emergent BioSolutions Inc. [ EBS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Quality & Ethics, and CPL

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/05/2026		F		8,199(1)	D	$8.44	104,108	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to buy)	$8.99	03/03/2026		A		44,834		(2)	03/02/2033	Common Stock	44,834	$0	294,447	D

Explanation of Responses:

1. Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units

2. Vests in three equal installments beginning on the day prior to the anniversary date of the grant.

Remarks:

	/s/ Richard S. Lindahl, Attorney-in-fact	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.